{"version":"1.0","provider_name":"PhinC Group","provider_url":"https:\/\/www.phinc-group.com\/en","author_name":"Mohamed Taourirt","author_url":"https:\/\/www.phinc-group.com\/en\/author\/mtaourirt\/","title":"\u00c9quilibrer l'Efficacit\u00e9 et la S\u00e9curit\u00e9 en Oncologie - PhinC Group","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"MFuSR0csXR\"><a href=\"https:\/\/www.phinc-group.com\/en\/equilibrer-lefficacite-et-la-securite-en-oncologie\/\">Balancing efficacy and safety in oncology<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.phinc-group.com\/en\/equilibrer-lefficacite-et-la-securite-en-oncologie\/embed\/#?secret=MFuSR0csXR\" width=\"600\" height=\"338\" title=\"&#8220;\u00c9quilibrer l&rsquo;Efficacit\u00e9 et la S\u00e9curit\u00e9 en Oncologie&#8221; &#8212; PhinC Group\" data-secret=\"MFuSR0csXR\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.phinc-group.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>","thumbnail_url":"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/11\/visuel-efficacite-et-tolerance.png","thumbnail_width":1000,"thumbnail_height":750,"description":"Au cours de la derni\u00e8re d\u00e9cennie, le d\u00e9veloppement de m\u00e9dicaments en oncologie est pass\u00e9 d'une forte d\u00e9pendance \u00e0 la \u00ab dose maximale tol\u00e9r\u00e9e \u00bb (MTD) \u00e0 un encouragement actif des approches sur mesure inform\u00e9es par la mod\u00e9lisation. La FDA a officialis\u00e9 ses attentes par le biais d'initiatives sp\u00e9cifiques comme le Projet Optimus poussant \u00e0 une optimisation des doses qui \u00e9quilibre efficacit\u00e9 et toxicit\u00e9."}